Pediatric Orofacial and Laryngopharyngeal Rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma Study Report

Moody D. Wharam, Mohan S. Beltangady, Ruth M. Heyn, Walter Lawrence, R. Beverly Raney, Frederick B. Ruymann, Edward H. Soule, Melvin Tefft, Harold M. Maurer

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Eighty-nine children with localized rhabdomyosarcoma of orofacial and laryngopharyngeal sites were treated in accordance with the first and second Intergroup Rhabdomyosarcoma Study (IRS) protocols (IRS-I and IRS-II) between 1972 and 1984. Treatment included surgery (or biopsy) and chemotherapy for all patients and radiotherapy in the majority. The actuarial estimate of the three-year survival rate for all patients was 83% and did not differ significantly by primary site, histologic findings, or presence of adenopathy. A trend for a worse survival rate was seen in clinical group III patients and in those less than 5 years of age at diagnosis. Factors associated with an increased risk of local/regional relapse included omission of radiotherapy and a radiation dose of less than 40 Gy (4000 rad). We conclude that treatment of these patients as recommended in the IRS-I and IRS-II protocols results in very good local and regional tumor control and survival rates. Salvage therapy for local/regional recurrence may yield long-term remission and possibly cure.

Original languageEnglish (US)
Pages (from-to)1225-1227
Number of pages3
JournalArchives of Otolaryngology--Head and Neck Surgery
Issue number11
StatePublished - Nov 1987

ASJC Scopus subject areas

  • Surgery
  • Otorhinolaryngology


Dive into the research topics of 'Pediatric Orofacial and Laryngopharyngeal Rhabdomyosarcoma: An Intergroup Rhabdomyosarcoma Study Report'. Together they form a unique fingerprint.

Cite this